Genetically engineered antigen specificity in T cells for adoptive immunotherapy

0Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Antigen specificity has been genetically conferred to human T cells for therapy through the transfer of sequences encoding antigen-specific T-cell receptors (TCRs) or through the antigen-specific antibody-based chimeric antigen receptors (CARs). By either method, the advantage of the adoptive transfer of modified T cells over immunotherapies developed to date such as vaccines or cytokines alone is that T cells have the ability to directly traffic to the site of tumor or infection, to multiply at that site, and to persist in a memory state for months to years.

Cite

CITATION STYLE

APA

Powell, D. J., & Levine, B. L. (2011). Genetically engineered antigen specificity in T cells for adoptive immunotherapy. In Experimental and Applied Immunotherapy (pp. 251–278). Humana Press Inc. https://doi.org/10.1007/978-1-60761-980-2_12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free